重组人干扰素α-2b雾化治疗联合人免疫球蛋白治疗新生儿合胞病毒性肺炎的临床疗效研究

Clinical Efficacy of Recombinant Human Interferonα-2b Atomization Therapy Combined with Human Immunoglobulin in the Treatment of Neonatal Syncytial Virus Pneumonia

目的探讨重组人干扰素α-2b雾化治疗联合人免疫球蛋白治疗新生儿合胞病毒性肺炎的临床疗效研究。方法选取2018年2月-2021年2月在本院住院就诊的合胞病毒性肺炎新生儿120例,按照随机数字表法将患儿分为观察组和对照组,每组各60例。对照组使用重组人干扰素α-2b雾化治疗7d,观察组在治疗组的基础上联合给予静注用人免疫球蛋白持续治疗3d。观察两组患者的临床疗效、哮鸣音持续时间、咳嗽持续时间、喘憋持续时间、血清IgE和T淋巴细胞亚群CD3^(+)水平和药物不良反应。结果观察组的临床有效率为95.00%,对照组的临床有效率为90.00%,两组患者的临床有效率比较差异无统计学意义(P>0.05)。观察组的哮鸣音持续时间、咳嗽持续时间、喘憋持续时间比对照组明显更短,差异具有统计学意义(P<0.05)。治疗后,两组患者的血清IgE水平都降低,T淋巴细胞亚群CD3^(+)水平升高,且观察组的幅度更大(P<0.05)。两组患者在住院期间都未发生严重的药物不良反应。结论重组人干扰素α-2b雾化联合人免疫球蛋白治疗新生儿合胞病毒性肺炎没有显著提升临床疗效,但是可以明显缩短哮鸣音持续时间、咳嗽持续时间、喘憋持续时间,且安全性良好,可作为新生儿合胞病毒性肺炎的推荐治疗方案。

Objective To study clinical efficacy of recombinant human interferonα-2b atomization therapy combined with human immunoglobulin in the treatment of neonatal syncytial virus pneumonia.Methods 120 newborns with syncytial virus pneumonia hospitalized in our hospital from February 2018 to February 2021 were randomly divided into observation group and control group,with 60 cases in each group.The control group was treated with recombinant human interferonα-2b atomization treatment for 7 days,the observation group was given intravenous injection of human immunoglobulin on the basis of the treatment group for 3 days.The clinical efficacy,wheezing duration,cough duration,wheezing duration,serum IgE and CD3+levels of T lymphocyte subsets and adverse drug reactions were observed.Results The clinical effective rate of the observation group was 95.00%,the clinical effective rate of the control group was 90.00%.There was no significant difference between the two groups(P>0.05).The duration of wheezing,cough and wheezing in the observation group were significantly shorter than those in the control group(P<0.05).After treatment,the levels of serum IgE and CD3+of T lymphocyte subsets increased in both groups,and the range in the observation group was greater(P<0.05).No serious adverse drug reactions occurred in both groups during hospitalization.Conclusion Recombinant human interferonα-2b atomization combined with human immunoglobulin in the treatment of neonatal syncytial virus pneumonia does not significantly improve the clinical efficacy,but it can significantly shorten the duration of wheezing,cough and wheezing,and has good safety.It can be used as the recommended treatment for neonatal syncytial virus pneumonia.